Hua Medicine In-licenses Diabetes Drug Candidate from Roche

Hua Medicine has in-licensed global rights to Roche’s glucokinase activator program (GKA), a potential treatment for diabetes. GKA is a novel, small molecule activator of the glucokinase enzyme, which helps to regulate carbohydrate metabolism. The product,Hua's first in-licensing, is ready to start clinical trials. In return for exclusive global development, manufacturing and marketing rights, Hua has agreed to pay an upfront payment, milestones and royalties. More details.... Stock Symbol: (SIX: ROG)